These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38163322)

  • 1. Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease.
    Dawwas GK; Cuker A; Schaubel DE; Lewis JD
    Blood Adv; 2024 Mar; 8(5):1272-1280. PubMed ID: 38163322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients.
    Ra G; Thanabalan R; Ratneswaran S; Nguyen GC
    J Crohns Colitis; 2013 Nov; 7(10):e479-85. PubMed ID: 23537817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism.
    Scharrer S; Primas C; Eichinger S; Tonko S; Kutschera M; Koch R; Blesl A; Reinisch W; Mayer A; Haas T; Feichtenschlager T; Fuchssteiner H; Steiner P; Ludwiczek O; Platzer R; Miehsler W; Tillinger W; Apostol S; Schmid A; Schweiger K; Vogelsang H; Dejaco C; Herkner H; Novacek G;
    Inflamm Bowel Dis; 2021 Oct; 27(11):1773-1783. PubMed ID: 33386735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unawareness of thromboprophylaxis is associated with low venous thromboembolism occurrence in hospitalized patients with acute inflammatory bowel disease flare.
    Sbeit W; Kadah A; Shafrir A; Kalisky I; Mahamid M; Hazou W; Katz L; Mari A; Khoury T
    Minerva Med; 2020 Dec; 111(6):560-565. PubMed ID: 32729705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease.
    Lobo JL; Garcia-Fuertes JA; Trujillo-Santos J; Merah A; Blanco-Molina MÁ; Casado I; Hirmerova J; De Miguel J; Salgado E; Monreal M;
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):526-530. PubMed ID: 29462026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
    Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
    Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan.
    Adomi M; Kuno T; Komiyama J; Taniguchi Y; Abe T; Miyawaki A; Imai S; Morita K; Saito M; Ohbe H; Kamio T; Tamiya N; Iwagami M
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):680-688. PubMed ID: 35324035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis.
    Nguyen GC; Bernstein CN
    Am J Gastroenterol; 2013 Sep; 108(9):1486-95. PubMed ID: 23857476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation.
    Poletto F; Spiezia L; Simion C; Campello E; Dalla Valle F; Tormene D; Camporese G; Simioni P
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
    Kang HR; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Park H
    Clin Pharmacol Ther; 2022 Jul; 112(1):133-145. PubMed ID: 35420702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
    Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
    Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral anticoagulation in ambulatory patients with cancer.
    Akl EA; Kahale LA; Hakoum MB; Matar CF; Sperati F; Barba M; Yosuico VED; Terrenato I; Synnot A; Schünemann H
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD006652. PubMed ID: 28892556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: a nationwide cohort study.
    Heo CM; Kim TJ; Kim ER; Hong SN; Chang DK; Yang M; Kim S; Kim YH
    Sci Rep; 2021 Jan; 11(1):2025. PubMed ID: 33479464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.
    Vaughn VM; Yost M; Abshire C; Flanders SA; Paje D; Grant P; Kaatz S; Kim T; Barnes GD
    JAMA Netw Open; 2021 Jun; 4(6):e2111788. PubMed ID: 34115129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.